$AIDX News
Last published 6d ago
- 6d agoAIDXREMINDER TO VOTE: 20/20 BioLabs Special Meeting of Stockholders to Be Held December 9, 2026GlobeNewswireBoard of Directors Recommends a Vote FOR Each Proposal, Including a Reverse Stock Split Authorization Intended to Provide Flexibility to Regain Compliance with Nasdaq’s $1.00 Minimum Bid Price Requirement Stockholders
- 1w agoAIDX20/20 BioLabs to Host November 4 Investor Webinar on OneTest™ Commercial Expansion and Growth StrategyGlobeNewswireCEO Jonathan Cohen to Discuss Laboratory Franchise Model, 2027 Licensing Plans, Potential Acquisitions, FDA Strategy, and Firefighter Cancer Screening Initiatives Webinar to Be Held Wednesday, November 4, 2026 at 12:00
- 2mo agoAIDX20/20 BioLabs Reschedules Investor Webinar to 2:00 p.m. Eastern Time on September 2, 2026 to Discuss OneTest™ Revenue and Expanding Commercial OpportunityGlobeNewswireCEO Jonathan Cohen to Detail the Company’s Strongest Quarterly Performance Since Commercial Launch of Multi-Cancer Early Detection Testing, Key Takeaways from the Next Generation Dx Summit, and Path to Broader
- 2mo agoAIDX20/20 BioLabs to Host Investor Webinar on September 2, 2026 to Discuss OneTest™ Revenue and Expanding Commercial OpportunityGlobeNewswireCEO Jonathan Cohen to Detail the Company’s Strongest Quarterly Performance Since Commercial Launch of Multi-Cancer Early Detection Testing, Key Takeaways from the Next Generation Dx Summit, and Path to Broader
- 2mo agoAIDX20/20 BioLabs Reports Second Quarter 2026 Financial Results and Recent Operational Progress, as Cancer Test Revenue Reaches Record Quarterly LevelGlobeNewswireBest Quarter of Flagship Multi-Cancer Early Detection Testing; OneTest™ Revenue Increased 47% Year-Over-Year to $0.7 Million; Gross Profit Increased 87% to $0.3 Million, with Gross Margin Expanding to 41.7% from 30.5%
- 3mo agoAIDX20/20 BioLabs to Host Investor Webinar on August 5, 2026, to Discuss Commercial Opportunities Following Management’s Recent East Asia Business Development TourGlobeNewswireChief Executive Officer Jonathan Cohen to Discuss BIO Asia-Taiwan Participation and Strategic Meetings in Taipei, Tokyo, and Seoul Webinar to Be Held Wednesday, August 5, 2026 at 12:00 p.m. Eastern Time; Registration
- 3mo agoAIDX20/20 BioLabs Participates in BIO Asia-Taiwan and Meets with Strategic Counterparties in Taipei, Tokyo, and Seoul to Advance East Asia Roll-Up StrategyGlobeNewswireManagement Met with Potential Acquisition, Licensing, Joint Venture, and Commercial Partners Across the Region Initiative Aims to Expand Mission of Saving Lives Through Early Detection and Prevention of Cancers and
- 3mo agoAIDX20/20 BioLabs Announces Standstill Agreement with Streeterville Capital Regarding Series E Convertible Preferred StockGlobeNewswireAgreement Temporarily Restricts Preferred-to-Common Stock Conversions Below a Defined Price Threshold, Mitigating Potential Near-Term Dilution GAITHERSBURG, Md., July 23, 2026 (GLOBE NEWSWIRE) -- 20/20 BioLabs, Inc.
- 4mo agoAIDX20/20 BioLabs Announces Monthly Investor Webinar Series to be Held on the First Wednesday of Each MonthGlobeNewswireInaugural Session to be Held Wednesday, July 1, 2026, at 12:00 p.m. ET Recurring Forum Intended to Increase Transparency, Strengthen Shareholder Communication, and Provide Investors with Direct Access to Management
- 5mo agoAIDX20/20 Biolabs' Multi-Cancer Early Detection Blood Test Selected by State of Vermont to Screen up to 4,500 FirefightersGlobeNewswireComprehensive Cancer Screening Initiative Expected to Generate Approximately $500,000 in Testing Revenues to 20/20 from the First Cohort GAITHERSBURG, Md., May 27, 2026 (GLOBE NEWSWIRE) -- 20/20 Biolabs, Inc.
- 5mo agoAIDX20/20 Biolabs Commences Emergency Planning for Ebola & Hantavirus Lab Testing if Outbreak Creates Overflow DemandGlobeNewswireCompany to Draw on Substantial Experience with COVID Testing to Again Support Public Health Agencies if Needed GAITHERSBURG, Md., May 22, 2026 (GLOBE NEWSWIRE) -- 20/20 Biolabs, Inc. (Nasdaq: AIDX) ("20/20 Biolabs"
- 5mo agoAIDX20/20 BioLabs Reports First Quarter 2026 Financial Results and Recent Operational ProgressGlobeNewswireState-Funded Firefighter Cancer Screening Programs Expected to Drive Meaningful Revenue Growth Beginning in Q2 2026 $5.0 Million Private Placement Strengthens Cash Position to $4.2 Million as of March 31, 2026 Recent
- 5mo agoACUAIDXAZBSET+11Sidoti Events, LLC's May Micro-Cap Virtual ConferenceACCESS NewswireNEW YORK, NY / ACCESS Newswire / May 20, 2026 / Sidoti Events, LLC, an affiliate of Sidoti & Company, LLC, has released the presentation schedule and weblinks for its two-day May Micro-Cap Virtual Investor Conference
- 6mo agoAIDX20/20 BioLabs to Attend Sidoti Micro-Cap Virtual Conference on May 20, 2026GlobeNewswireGAITHERSBURG, Md., May 14, 2026 (GLOBE NEWSWIRE) -- 20/20 BioLabs, Inc. ("20/20") (NASDAQ:AIDX), an early market entrant in cutting-edge, AI powered laboratory-based blood tests for the early detection and prevention
- 6mo agoAIDX20/20 BioLabs Exclusively Licenses PSA Velocity Algorithm from the University of South CarolinaGlobeNewswirePatented Algorithm Designed to Help Identify Otherwise Dangerous Prostate Tumors Earlier Using Repeat Blood Test Results Licensing Agreement Expands 20/20 BioLabs' AI-Enabled Multi-Cancer Early Detection Platform
- 7mo agoAIDX20/20 BioLabs Selected by Evexia Diagnostics to Offer OneTest™ for Cancer Through Evexia PlatformGlobeNewswireJoint Release Expands 20/20 BioLabs' Testing Solutions Across Evexia's Network of ~40,000 Functional and Integrative Medicine Practitioners Marks a Commercial Expansion Milestone for OneTest for Cancer Across Evexia's
- 7mo agoAIDX20/20 BioLabs Reports Full Year 2025 Financial Results and Recent Operational ProgressGlobeNewswireFull Year 2025 Revenue of $2.0 Million, up 17% from 2024 Gross Profit Increased 68% in FY 2025 and Gross Margin Expanded 900 bps State-Funded Firefighter Cancer Screening Program Expected to Drive Significant Revenue
- 7mo agoAIDXMaryland Fire Departments Awarded $520,000 for Cancer Screenings using 20/20 BioLabs' OneTest ™ Multi-Cancer Early Detection Blood TestGlobeNewswireState-Funded Screening Initiative Highlights Growing Public Sector Support for Innovative Cancer Detection Tools GAITHERSBURG, Md., March 27, 2026 (GLOBE NEWSWIRE) -- 20/20 BioLabs, Inc. (NASDAQ:AIDX), an early
- 7mo agoAIDX20/20 BioLabs Announces Exclusive U.S. License Agreement with ROKIT Healthcare to Integrate Advanced CKD Prediction Technology into Its Longevity Test ProgramGlobeNewswireInflammatory Biomarker Tracking Predicted to Enhance Response to 3-D Bio-Printed Therapies Expands OneTest for Longevity with Chronic Kidney Disease Risk Assessment GAITHERSBURG, Md., March 24, 2026 (GLOBE
- 8mo agoAIDX20/20 BioLabs Highlights Advantages of its Patented Protein Biomarker Technology for Multi-Cancer Early Detection in Light of Recent StudiesGlobeNewswireGAITHERSBURG, M.D., March 12, 2026 (GLOBE NEWSWIRE) -- 20/20 BioLabs (NASDAQ:AIDX), an early market entrant in cutting-edge, AI powered laboratory-based blood tests for the early detection and prevention of cancers and
- 8mo agoAIDX20/20 BioLabs Launches OneTest for Longevity Blood Test and Chronic Disease Risk Assessment and Management Solution Built with IBM AI CapabilitiesGlobeNewswireRecently Nasdaq-Listed Company Introduces Longevity Blood Test Integrating Inflammatory Biomarkers, Dietary Habits, and Curated Scientific Research to Deliver Personalized Health Insights GAITHERSBURG, Md., Feb. 25,
- 8mo agoAIDX20/20 BioLabs to Host Virtual Investor Webinar on Thursday, February 26, 2026 at 2:00 p.m. Eastern TimeGlobeNewswireGAITHERSBURG, Md., Feb. 20, 2026 (GLOBE NEWSWIRE) -- 20/20 BioLabs, Inc. (NASDAQ:AIDX), an early market leader in cutting-edge, AI-powered laboratory-based blood tests for the early detection and prevention of
- 8mo agoAIDX20/20 BioLabs Debuts Trading on Nasdaq Under Ticker Symbol "AIDX" Following 3 Consecutive Years of Sales GrowthGlobeNewswireCompany Ready to Scale Growth through OneTest™ AI-Powered Blood Tests for Cancer and Longevity GAITHERSBURG, Md., Feb. 19, 2026 (GLOBE NEWSWIRE) -- 20/20 BioLabs, Inc. (NASDAQ:AIDX), an early market leader in